Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
about
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerTargeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast CancerEverolimus in the Treatment of Metastatic Breast CancerTen things you should know about protein kinases: IUPHAR Review 14Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantEverolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysisEverolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.Treatment options in HR⁺/HER2⁻ advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer.Safety of mTOR inhibitors in breast cancer.Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.ABC4 Consensus: Assessment by a German Group of ExpertsLow serum gastrin associated with ER breast cancer development via inactivation of CCKBR/ERK/P65 signaling
P2860
Q26741153-EB355199-EA66-4450-94BF-0BBEC776DF1AQ26770482-261420CF-AA2E-4D5C-BC4E-AA18D74ED2CCQ26775361-8553AB3C-8B54-4A3F-8C4B-F48CB9645637Q26777734-CA72956B-3D99-42B6-B17F-4B4D65CD6C96Q26784920-42B6E565-871A-4FED-911D-5C4969E9FC2AQ26849417-92CF53D9-948A-4D0D-9261-D2B933B4EEDAQ28076777-963DEDE8-C308-47C6-9EE2-07145B4DE779Q28085004-F52628C4-DBFE-47F3-8D4D-23CA9B7A7749Q33727284-40A1E566-A06E-4EF5-AA39-BF5F72BB4619Q34352887-0DB65266-05D0-432C-94DB-F1A44F4B23A5Q35675851-D7A924D2-EDC2-4799-8F33-49091F1E54CAQ35826810-F5C0E7B6-D621-4F1D-BCFC-C24EBCF2AB1DQ36078905-0058C1C5-EAA0-4506-96EC-8E42C3661632Q36355880-1567FDDA-069D-4B54-953D-CA7F1F9B5401Q38250444-D8DF7DCF-E19B-45CD-B587-E7C56285864FQ38502890-EB3D1DAF-0D50-48B3-BB04-C7EA16DC4841Q38690803-D0125B68-95BF-446A-A295-3FB096ECED96Q38841039-5444B49D-8486-4B45-856F-13DCF6B5A5A4Q38852355-A3F8A36B-9CAD-444E-AFDA-1F9A6E41853BQ39172983-35F8E5D6-0345-4F29-9D69-4947548120BEQ40126367-482449D0-E3C4-47EB-A6B9-0FD25DC7E915Q40814112-081B0E1B-F322-4A3E-8F4D-343BD29A8F9CQ46605325-539EBE65-5DB3-4131-88B8-72D40D768F17Q47825566-83383388-F1D3-44CC-8079-28A7B46E0252Q48342762-7F8176DC-3CCE-46D1-82D9-C3619136366AQ49970203-9C644568-0A48-4FA2-80CD-92411BFB1675Q52642671-D43C1B8E-AE9D-41A9-87B2-11731560EA38Q55339569-D9F8D7F1-FC8F-4F67-A91D-6EEC8B644ECDQ55346396-8BE58482-A94F-48C0-8A8C-D64B2CFB797FQ56968314-AD50A98C-8C7A-49C7-AC1A-5D01A6BE0E8FQ58774122-6A2EBA05-DBA5-4108-87C2-831DDAA92E56
P2860
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.
@en
Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.
@nl
type
label
Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.
@en
Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.
@nl
prefLabel
Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.
@en
Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.
@nl
P2093
P2860
P1476
Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.
@en
P2093
Barbara Pistilli
Bohuslav Melichar
Daniel Y C Heng
Fabienne Lebrun
Francois Ringeisen
Gabriel N Hortobagyi
Hope S Rugo
Ines Deleu
J Thaddeus Beck
Lowell Hart
P2860
P2888
P304
P356
10.1007/S10549-013-2814-5
P407
P577
2013-12-21T00:00:00Z